About us

Background

DELPHINIUM is a dedicated and dynamic company, comprised of experienced professionals committed to Phase I clinical trials. Our 12-bed Phase I clinic specializes in clinical studies conducted with healthy volunteers, offering a range of services including Project Management, Monitoring, Data Management, Bioanalysis and more.

Our mission is to deliver high-quality, tailor-made Phase I clinical studies in which we prioritize efficient and direct communication between Sponsors and researchers to ensure a flexible, fast and adaptive approach to your clinical program. At DELPHINIUM, we are committed to excellence and precision in every aspect, ensuring the success of your clinical trials.

Challenges

We recognize the unique challenges faced by biotech companies in executing Phase I programs with tight timelines and limited budgets. Partner with DELPHINIUM to collaborate with a CRO that is fully committed to addressing your challenges and helping you achieve your clinical trial goals.

We believe that the combination of experience, dedication, and a personalized approach leads to the highest quality outcomes, even when unforeseen events arise. Together, we can advance the frontiers of medical science.

Our management

Christine Voors-Pette, MD has been working as a Principal Investigator for over 15 years in both early- and late phase clinical research. She performed over 50 early phase clinical studies, with the majority being First-in-human trials. She is known for her straight forward approach, open communication and her commitment to clients, volunteers and coworkers.

Jitske Beukema brings a wealth of knowledge and experience within pharmaceutical and Biotech industry. She is an accomplished and proven senior executive with more than 30 years of experience in Phase I healthy volunteer and patient studies.

Agnes Boelens-van Nieff has been working for 20 years as Management Assistant/Sr. Clinical Trial Assistant/Regulatory Affairs Specialist. She will be responsible for regulatory affairs and financial affairs.